Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.

[1]  B. de Strooper,et al.  The Cell Adhesion Protein P-selectin Glycoprotein Ligand-1 Is a Substrate for the Aspartyl Protease BACE1* , 2003, Journal of Biological Chemistry.

[2]  M. Citron,et al.  BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time , 2003, Neurobiology of Disease.

[3]  Tam Doan,et al.  Antagonistic Effects of β-Site Amyloid Precursor Protein-cleaving Enzymes 1 and 2 on β-Amyloid Peptide Production in Cells* , 2003, Journal of Biological Chemistry.

[4]  B. Greenberg,et al.  The Mechanism of γ-Secretase , 2003, Journal of Biological Chemistry.

[5]  F. Checler,et al.  BACE1- and BACE2-expressing Human Cells , 2003, Journal of Biological Chemistry.

[6]  S. Yamazaki,et al.  The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice , 2003, Journal of Pharmacology and Experimental Therapeutics.

[7]  S. Kitazume,et al.  Characterization of α2,6-Sialyltransferase Cleavage by Alzheimer's β-Secretase (BACE1)* , 2003, The Journal of Biological Chemistry.

[8]  Eugene D. Thorsett,et al.  Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. , 2003, Journal of medicinal chemistry.

[9]  B. Strooper,et al.  Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex , 2003, Neuron.

[10]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[11]  B. Dunn,et al.  Aspartic Peptidase Inhibitors: Implications in Drug Development , 2003, Critical reviews in biochemistry and molecular biology.

[12]  C. Haass,et al.  Alzheimer disease γ-secretase: a complex story of GxGD-type presenilin proteases , 2002 .

[13]  A. Palmer.  Pharmacotherapy for Alzheimer's disease: progress and prospects. , 2002, Trends in pharmacological sciences.

[14]  B. Hyman,et al.  Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.

[15]  D. Selkoe,et al.  The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics , 2002, Science.

[16]  C. Masters,et al.  Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease , 2002 .

[17]  Sangram S. Sisodia,et al.  γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in? , 2002, Nature Reviews Neuroscience.

[18]  M. Staufenbiel,et al.  Expression of human β‐secretase in the mouse brain increases the steady‐state level of β‐amyloid , 2002 .

[19]  C. Masters,et al.  Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma -secretase inhibitor: implications for presenilin biology. , 2001, The Journal of biological chemistry.

[20]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[21]  S. Kitazume,et al.  Alzheimer's β-secretase, β-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Lars Bertram,et al.  New Frontiers in Alzheimer's Disease Genetics , 2001, Neuron.

[23]  Lin Hong,et al.  Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design† , 2001 .

[24]  Arun K. Ghosh,et al.  Structure-Based Design: Potent Inhibitors of Human Brain Memapsin 2 (β-Secretase) , 2001 .

[25]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[26]  G. Multhaup,et al.  A Splice Variant of β-Secretase Deficient in the Amyloidogenic Processing of the Amyloid Precursor Protein* , 2001, The Journal of Biological Chemistry.

[27]  N K Hollenberg,et al.  Is there a future for renin inhibitors? , 2001, Expert opinion on investigational drugs.

[28]  H. Cai,et al.  BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.

[29]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.

[30]  C. Southan,et al.  ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the β-Secretase Site , 2000, Molecular and Cellular Neuroscience.

[31]  L Hong,et al.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.

[32]  C. Schnitzler,et al.  BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein , 2000 .

[33]  M. Citron,et al.  Expression Analysis of BACE2 in Brain and Peripheral Tissues* , 2000, The Journal of Biological Chemistry.

[34]  Min Xu,et al.  Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1 , 2000, Nature.

[35]  F. D. Miller,et al.  Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.

[36]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[37]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[38]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[39]  Rudolph E. Tanzi,et al.  BACE Maps to Chromosome 11 and a BACE Homolog, BACE2, Reside in the Obligate Down Syndrome Region of Chromosome 21 , 1999 .

[40]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[41]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[42]  Sarah Tomlin,et al.  Microtechnology: Laying it on thick , 1999, Nature.

[43]  S. Enna,et al.  Pharmacological Management of Neurological and Psychiatric Disorders , 1998 .

[44]  S. Younkin.  The role of Aβ42 in Alzheimer's disease , 1998, Journal of Physiology-Paris.

[45]  D. Selkoe,et al.  The Seminal Role of β‐Amyloid in the Pathogenesis of Alzheimer Disease , 1992 .

[46]  P. Wong,et al.  Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.

[47]  D. Fairlie,et al.  Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.

[48]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.